Drug Profile
TAK 357
Alternative Names: TAK-357Latest Information Update: 13 May 2013
Price :
$50
*
At a glance
- Originator Takeda
- Class Nootropics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 10 May 2013 Discontinued - Phase-I for Alzheimer's disease (PO)
- 31 Jul 2012 Phase-I clinical trials in Alzheimer's disease (PO)